



PRESS RELEASE

IBA signs a non-binding letter of intent to provide Proton Therapy System for the University of Pennsylvania Health System

For immediate release – April 27, 2006

Louvain-la-Neuve, Belgium, April 27, 2006 – IBA (Ion Beam Application S.A.: Reuters IOBA:BR and Bloomberg IBAB:BB) announced today that it has signed a non-binding letter of intent with the University of Pennsylvania Health System (UPHS) to provide a proton therapy system for a new Proton Beam Therapy Center. This center will be operated by UPHS and integrated with its Raymond and Ruth Perelman Center for Advanced Medicine in downtown Philadelphia, PA, USA.

Following a rigorous selection process, Penn's Health System selected IBA for this large proton therapy system that will have up to 5 treatment rooms – 4 gantries (isocentric rotational frames) and one fixed beam room—with the most advanced options for patient positioning and nozzle technologies, in addition to one separate research room. This will make it the largest proton therapy center ever designed.

The center will take about 3 years to start operation, with the first patient expected to be treated in 2009. The proton therapy and related equipment provided by IBA are worth approximately \$60 million. The parties have agreed to a three month exclusive negotiation period to finalize the terms of the contract. Due to the long lead time for the procurement of the key material items, if a contract is signed by end of June, it is not expected to have material financial impact on the IBA results for 2006 but will significantly contribute to the years 2007 to 2009.

Considering the announcement end of March 2006, that IBA was selected to build a Proton therapy center at Hampton University, Hampton, Virginia, USA (subject to financing), IBA has now been selected by 5 leading institutions in the United States to provide a proton therapy system. The first one is located at the Massachusetts General Hospital, Harvard University Hospital Campus, Boston, USA, and has been treating patients since November 2001. The second center is located at the Midwest Proton Radiotherapy Institute, Indiana University, Bloomington, Indiana, USA, for which IBA provided gantries for two treatment rooms, with the first patient having received treatment during summer 2004. And the third facility, located at the Florida Proton Therapy Institute in Jacksonville, Florida, USA, in partnership with the University of Florida, is scheduled to open in the second part of 2006.

We are very pleased by this recognition of the unique benefits our company and our integrated proton therapy system can bring. The fact that we are the only proton therapy company with several centers treating patients around the world has certainly played an important role. We are now very excited by the prospects to develop proton therapy in partnership with such a prestigious institution as UPHS and to see the unique benefits of proton therapy made available to even more patients” said Pierre Mottet, IBA's Chief Executive Officer.



PRESS RELEASE

About IBA

IBA delivers efficient, dependable solutions of a unique precision in the fields of cancer diagnosis and therapy. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to BelSmall index. Site : <http://www.iba-worldwide.com>.

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Phone: +32 10 47 58 16
paul.emmanuel-goethals@iba-group.com